Skip to Content

Singular Focus

To effectively impact patient care, IACS programs are selected for their ability to change the course of disease. Three elements are integral considerations for each program that becomes part of IACS’s portfolio because they are central components of clinical success: adequate knowledge of target biology, selection of proper drug properties, and treatment of the appropriate patient population.

IACS programs are the result of close collaborations with MD Anderson investigators, as well as extensive landscape analysis.

IACS conducts an extensive upfront evaluation of all potential targets, specifically considering: (1) Disease Relevance – impact on tumor development and maintenance; (2) Tractability – potential for therapeutic attack; and (3) Translatability – potential for clinical development. Potential targets are continually reviewed and this upfront robust research allows IACS to move quickly to pre-defined go/no-go experiments once a project becomes part of the portfolio.

Team members are committed to advancing a pipeline of safe and effective drug candidates into the clinic and with careful program management IACS looks to mature into a self-sustaining venture.

Newsletter

MD Anderson Hightlights

External Media Coverage

Join our Team

Contact Us

Institute for Applied Cancer Science
MD Anderson Cancer Center
1901 East Road
Houston TX 77054
Tel: 713-745-2600

For questions concerning collaborations or partnerships, please contact:

Eric Devroe
Executive Director of Strategic Alliances
EJDevroe@mdanderson.org

We need your help

Philanthropic support will provide IACS several critical advantages that will ultimately benefit cancer patients by providing them with novel treatments in a shorter timeframe. If you’re interested in advancing this transformative venture, please donate through the myGiving site.


© 2013 The University of Texas MD Anderson Cancer Center